Loading
A phase 3 trial of Nivolumab, Epacadostat, Carboplatin, Cisplatin, Gemcitabine, Paclitaxel / nab-paclitaxel and Pemetrexed in Lung cancer, run by Incyte Corporation, recorded as terminated on the registry.
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT03348904 by Incyte Corporation, with 2 participants recorded, started 2017-12-27 and due to reach its primary completion in 2018-05-22. Interventions recorded: Nivolumab, Epacadostat, Placebo, Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, Pemetrexed. Conditions recorded: Lung Cancer.
Linked to the drug Epacadostat because the registry names it among its interventions and Lung cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Epacadostat, Incyte, Cisplatin, Carboplatin and the tag pipeline.
Shares Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin, Lung cancer (all types) and the tag pipeline.
Shares Epacadostat, Incyte and the tag pipeline.
Shares Pemetrexed, Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Gemcitabine, Cisplatin and the tag pipeline.
Shares Gemcitabine, Nivolumab, Cisplatin, Carboplatin and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin and the tag pipeline.
Shares Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.